Psychedelics As a Treatment for Disorders of Consciousness

Overview

Journal Neurosci Conscious

Publisher Oxford University Press

Date 2019 Apr 27

PMID 31024740

Citations 25

Authors

Gregory Scott

Robin L Carhart-Harris

Affiliations

Soon will be listed here.

Abstract

Based on its ability to increase brain complexity, a seemingly reliable index of conscious level, we propose testing the capacity of the classic psychedelic, psilocybin, to increase conscious awareness in patients with disorders of consciousness. We also confront the considerable ethical and practical challenges this proposal must address, if this hypothesis is to be directly assessed.

Citing Articles

Brain health: A concern for anaesthesiologists and intensivists.

Bonhomme V, Putensen C, Bottiger B, Stevens M, Marczin N, Arnal D Eur J Anaesthesiol Intensive Care. 2025; 3(6):e0063.

PMID: 39917635 PMC: 11798402. DOI: 10.1097/EA9.0000000000000063.

The Dipeptidyl Peptidase-4 Inhibitor Saxagliptin as a Candidate Treatment for Disorders of Consciousness: A Deep Learning and Retrospective Clinical Analysis.

Toker D, Chiang J, Vespa P, Schnakers C, Monti M Neurocrit Care. 2025; .

PMID: 39904872 DOI: 10.1007/s12028-025-02217-0.

A pilot human study using ketamine to treat disorders of consciousness.

Cardone P, Bonhomme A, Bonhomme V, Lejeune N, Staquet C, Defresne A iScience. 2025; 28(1):111639.

PMID: 39886463 PMC: 11780106. DOI: 10.1016/j.isci.2024.111639.

Whole brain modelling for simulating pharmacological interventions on patients with disorders of consciousness.

Mindlin I, Herzog R, Belloli L, Manasova D, Monge-Asensio M, Vohryzek J Commun Biol. 2024; 7(1):1176.

PMID: 39300281 PMC: 11413186. DOI: 10.1038/s42003-024-06852-9.

Restoring consciousness with pharmacologic therapy: Mechanisms, targets, and future directions.

Barra M, Solt K, Yu X, Edlow B Neurotherapeutics. 2024; 21(4):e00374.

PMID: 39019729 PMC: 11452330. DOI: 10.1016/j.neurot.2024.e00374.

References

Wu D, Cai G, Yuan Y, Liu L, Li G, Song W . Application of nonlinear dynamics analysis in assessing unconsciousness: a preliminary study. Clin Neurophysiol. 2010; 122(3):490-498. DOI: 10.1016/j.clinph.2010.05.036. View

Tononi G, Boly M, Massimini M, Koch C . Integrated information theory: from consciousness to its physical substrate. Nat Rev Neurosci. 2016; 17(7):450-61. DOI: 10.1038/nrn.2016.44. View

Schartner M, Pigorini A, Gibbs S, Arnulfo G, Sarasso S, Barnett L . Global and local complexity of intracranial EEG decreases during NREM sleep. Neurosci Conscious. 2018; 2017(1):niw022. PMC: 6007155. DOI: 10.1093/nc/niw022. View

Passie T, Seifert J, Schneider U, Emrich H . The pharmacology of psilocybin. Addict Biol. 2003; 7(4):357-64. DOI: 10.1080/1355621021000005937. View

Ciurleo R, Bramanti P, Calabro R . Pharmacotherapy for disorders of consciousness: are 'awakening' drugs really a possibility?. Drugs. 2013; 73(17):1849-62. DOI: 10.1007/s40265-013-0138-8. View

Barre A, Berthoux C, De Bundel D, Valjent E, Bockaert J, Marin P . Presynaptic serotonin 2A receptors modulate thalamocortical plasticity and associative learning. Proc Natl Acad Sci U S A. 2016; 113(10):E1382-91. PMC: 4791007. DOI: 10.1073/pnas.1525586113. View

Carhart-Harris R, Goodwin G . The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology. 2017; 42(11):2105-2113. PMC: 5603818. DOI: 10.1038/npp.2017.84. View

Boulougouris V, Glennon J, Robbins T . Dissociable effects of selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial reversal learning in rats. Neuropsychopharmacology. 2007; 33(8):2007-19. DOI: 10.1038/sj.npp.1301584. View

Corazzol M, Lio G, Lefevre A, Deiana G, Tell L, Andre-Obadia N . Restoring consciousness with vagus nerve stimulation. Curr Biol. 2017; 27(18):R994-R996. DOI: 10.1016/j.cub.2017.07.060. View

10.

Olson D . Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics. J Exp Neurosci. 2018; 12:1179069518800508. PMC: 6149016. DOI: 10.1177/1179069518800508. View

11.

TORDA C . Contribution to serotonin theory of dreaming (LSD infusion). N Y State J Med. 1968; 68(9):1135-8. View

12.

Ly C, Greb A, Cameron L, Wong J, Barragan E, Wilson P . Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018; 23(11):3170-3182. PMC: 6082376. DOI: 10.1016/j.celrep.2018.05.022. View

13.

Berthoux C, Barre A, Bockaert J, Marin P, Becamel C . Sustained Activation of Postsynaptic 5-HT2A Receptors Gates Plasticity at Prefrontal Cortex Synapses. Cereb Cortex. 2018; 29(4):1659-1669. DOI: 10.1093/cercor/bhy064. View

14.

Bassett D, Gazzaniga M . Understanding complexity in the human brain. Trends Cogn Sci. 2011; 15(5):200-9. PMC: 3170818. DOI: 10.1016/j.tics.2011.03.006. View

15.

Frankel P, Cunningham K . The hallucinogen d-lysergic acid diethylamide (d-LSD) induces the immediate-early gene c-Fos in rat forebrain. Brain Res. 2002; 958(2):251-60. DOI: 10.1016/s0006-8993(02)03548-5. View

16.

Furr A, Lapiz-Bluhm M, Morilak D . 5-HT2A receptors in the orbitofrontal cortex facilitate reversal learning and contribute to the beneficial cognitive effects of chronic citalopram treatment in rats. Int J Neuropsychopharmacol. 2011; 15(9):1295-305. PMC: 3454536. DOI: 10.1017/S1461145711001441. View

17.

Bayne T, Carter O . Dimensions of consciousness and the psychedelic state. Neurosci Conscious. 2018; 2018(1):niy008. PMC: 6146157. DOI: 10.1093/nc/niy008. View

18.

Fins J, Illes J, Bernat J, Hirsch J, Laureys S, Murphy E . Neuroimaging and disorders of consciousness: envisioning an ethical research agenda. Am J Bioeth. 2008; 8(9):3-12. DOI: 10.1080/15265160802318113. View

19.

Giacino J, Fins J, Laureys S, Schiff N . Disorders of consciousness after acquired brain injury: the state of the science. Nat Rev Neurol. 2014; 10(2):99-114. DOI: 10.1038/nrneurol.2013.279. View

20.

Baars B . Global workspace theory of consciousness: toward a cognitive neuroscience of human experience. Prog Brain Res. 2005; 150:45-53. DOI: 10.1016/S0079-6123(05)50004-9. View